MSLE

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years. Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027 TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026. “The first quarter of 2026 was a productive time for Satellos. We raised $57M, providing runway to meet all planned milestones through the end of 2027, uplisted to Nasdaq, and advanced the Phase 2 TRAILHEAD and BASECAMP studies,” said Frank Gleeson, MBA, Chief Executive Officer of Satellos. “We are excited by the progress we are making with BASECAMP enrollment and dosing across 11 active clinical sites to date. We expect the additional sites intended to complete BASECAMP to be activated in Q2. We remain on track to complete BASECAMP enrollment in Q3 2026, supported by the active and planned sites currently having identified more than 100% of potential participants for screening and potential enrollment in the coming months.” SAT-3247 CLINICAL PROGRESS SAT-3247 is an orally administered small-molecule therapy designed to enhance muscle regeneration by addressing deficits in muscle stem cell polarity in Duchenne and potentially other muscle diseases. BASECAMP (CL-201): Phase 2 Pediatric Study The BASECAMP study is evaluating SAT-3247 in 51 ambulatory boys with DMD aged 7, 8 or 9 years. Primary endpoints include safety, tolerability and dynamometry. Secondary endpoints will assess SAT-3247’s impact on muscle quality, function and regeneration. The BASECAMP trial is actively enrolling at 11 clinical centers. The Company anticipates activating additional clinical sites throughout Q2 2026. TRAILHEAD (LT-001): Phase 2 Adult Study TRAILHEAD is a 12-month, open-label Phase 2 study evaluating long-term safety, efficacy and sustained functional benefit of SAT-3247 in adults with DMD. After submitting TRAILHEAD to the FDA in early Q2 2026 and following the statutory review period, Satellos began to engag...

TORONTO (AP) — TORONTO (AP) — Satellos Bioscience Inc. (MSLE) on Friday reported a loss of $9.8 million in its first quarter. The Toronto-based company said it had a loss of 53 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MSLE at https://www.zacks.com/ap/MSLE

TORONTO (AP) — TORONTO (AP) — Satellos Bioscience Inc. (MSLE) on Friday reported a loss of $7.3 million in its fourth quarter. On a per-share basis, the Toronto-based company said it had a loss of 47 cents. For the year, the company reported a loss of $24.9 million, or $1.70 per share. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MSLE at https://www.zacks.com/ap/MSLE

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy (“Duchenne” or “DMD”) Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 months Reported proteomic data from CL-101 (28-day Phase 1b trial in adults with DMD) at MDA, showing reductions in established biomarkers of muscle degeneration following SAT-3247 treatment Presented validation of a Regenerative Index (“RI”) biomarker at MDA, supporting its use to quantify muscle regeneration following SAT-3247 treatment and inform clinical interpretation; also presented new preclinical efficacy data in facioscapulohumeral muscular dystrophy (FSHD) Cash runway expected to extend through 2027 TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the full year ended Dec. 31, 2025. “2025 was a defining year for Satellos, and we are excited by the progress we have made across our clinical programs, including the initiation of two Phase 2 trials in Duchenne: BASECAMP, a placebo-controlled pediatric study, and TRAILHEAD, an open-label adult study,” said Satellos CEO Frank Gleeson. “Continued data from TRAILHEAD, where we observed greater improvements in participants with higher baseline muscle mass, has increased our confidence as we advance BASECAMP. We look forward to meaningful clinical progress and updates in 2026 supporting the potential of SAT-3247 as a disease-modifying therapy.” SAT-3247 CLINICAL PROGRESS SAT-3247 is an oral, small-molecule tablet designed to restore muscle regeneration by addressing deficits in muscle stem cell polarity in Duchenne and potentially other muscle diseases. BASECAMP (CL-201): Phase 2 Pediatric S...

Satellos Bioscience (MSCL.TO) said Friday that fiscal 2025 net loss widened on higher research expen